KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Revenue (2019 - 2025)

Historic Revenue for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to $87.3 million.

  • Esperion Therapeutics' Revenue rose 6909.86% to $87.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $303.8 million, marking a year-over-year increase of 282.65%. This contributed to the annual value of $332.3 million for FY2024, which is 18565.51% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Revenue is $87.3 million, which was up 6909.86% from $82.4 million recorded in Q2 2025.
  • Over the past 5 years, Esperion Therapeutics' Revenue peaked at $137.7 million during Q1 2024, and registered a low of $8.0 million during Q1 2021.
  • Its 5-year average for Revenue is $44.1 million, with a median of $32.2 million in 2023.
  • Its Revenue has fluctuated over the past 5 years, first plummeted by 8084.26% in 2021, then skyrocketed by 46613.51% in 2024.
  • Over the past 5 years, Esperion Therapeutics' Revenue (Quarter) stood at $15.4 million in 2021, then rose by 22.19% to $18.8 million in 2022, then skyrocketed by 71.38% to $32.2 million in 2023, then surged by 114.3% to $69.1 million in 2024, then rose by 26.33% to $87.3 million in 2025.
  • Its Revenue stands at $87.3 million for Q3 2025, versus $82.4 million for Q2 2025 and $65.0 million for Q1 2025.